Storify: Pathways to Access #GSIPA2M
[View the story “Pathways to Access! #GSIPA2M (15-17 Jan 2018)” on Storify] SaveSave
GSIPA2M: The Summit Highlights
Catch up on the activity from our inaugural Global Summit on Intellectual Property and Access to Medicines (15-17 January 2018)....
IP and access to medicines: welcome speech
Our inaugural Global Summit on Intellectual Property and Access to Medicines has started today. Read Solange Baptiste’s welcoming speech below,...
Pathways to Access: Our global summit on intellectual property and access to medicines
23 years after the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement was signed in Morocco, our inaugural conference...
Argentina: Patent rejected on hepatitis C drug, sofosbuvir
A decision by the patent office in Argentina (INPI) to reject Gilead’s patent on key hepatitis C drug, sofosbuvir, is...
‘Questionable’ patent on key HIV drug is challenged in Brazil
Legal challenge essential to prevent further barriers to optimal HIV treatment in Brazil. ABIA, our campaign partner in Brazil, is...
HIV activists trained on intellectual property and access to medicines
Demystifying intellectual property (IP) and providing advocacy tools. The International Treatment Preparedness Coalition – MENA (ITPC-MENA) with the support...
The Network vs. Abbvie – the first victory in reducing cost of HIV drug
The first victory has been won – and our partner in Ukraine intends to see the case through. On 4...
Patients demand AbbVie’s price bubble is burst – key HIV drug out of reach
AbbVie’s monopoly has hiked prices – it’s time to burst the bubble and get prices back down to earth. Activists...
Tackling the hepatitis C epidemic in Malaysia
With new, revolutionary, drugs available, why isn’t everyone getting the cure? An estimated 454,000 people are living with hepatitis C...